Inicio › Cáncer de pulmón › Massachusetts › Boston
Ensayos clínicos de Cáncer de pulmón en Boston, MA
63 estudios para Cáncer de pulmón buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
ReclutandoFase 2/3
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
ReclutandoSe aceptan voluntarios sanos
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
ReclutandoFase 2/3
- Dana-Farber Cancer Institute, Boston
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutandoFase 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
ReclutandoFase 3
- Tufts Medical Center, Boston
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
ReclutandoFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
ReclutandoEstudio observacional
- Massachusetts General Hospital, Boston
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Reclutando
- Massachusetts General Hospital, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
ReclutandoFase 3
- Massachusetts General Hospital, Boston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutandoFase 2
- Local Institution - 0124, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutando
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ReclutandoFase 3
- Boston Medical Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
Reclutando
- Dana-Farber Cancer Institute, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ReclutandoFase 1
- Research Site, Boston
- Research Site, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Reclutando
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
ReclutandoFase 2
- Research Site, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
ReclutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue From Patients With Lung Cancer
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)
ReclutandoEstudio observacional
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
ReclutandoFase 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
ReclutandoFase 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
ReclutandoEstudio observacional
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
ReclutandoFase 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
ReclutandoEstudio observacional
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
ReclutandoEstudio observacional
- Massachusetts General Hospital, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Reclutando
- Brigham and Women's Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
Reclutando
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Reclutando
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
ReclutandoEstudio observacional
- Dana-Farber Cancer Institute, Boston
Prediction Augmented Screening Initiative
Reclutando
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
ReclutandoFase 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
Reclutando
- Massachusetts General Hospital, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Reclutando
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
Reclutando
- Massachusetts General Hospital, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
ReclutandoSe aceptan voluntarios sanos
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
ReclutandoSe aceptan voluntarios sanos
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
ReclutandoFase 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
ReclutandoFase 1Se aceptan voluntarios sanos
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
ReclutandoSe aceptan voluntarios sanos
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Reclutando
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Image Guided VATS vs. VATS Resection
Reclutando
- Brigham and Women's Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
ReclutandoSe aceptan voluntarios sanos
- Dana Farber Cancer Institute, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
ReclutandoEstudio observacional
- Boston University Medical Center, Boston
Más información sobre Cáncer de pulmón en MedlinePlus
Ensayos de Cáncer de pulmón en otras ciudades
- Houston, TX78 estudios
- New York City, NY60 estudios
- Los Angeles, CA45 estudios
- Chicago, IL43 estudios
- Arlington, VA42 estudios
- Washington, DC41 estudios
- Baltimore, MD41 estudios
- Nashville, TN39 estudios
- St. Louis, MO37 estudios
- Columbus, OH36 estudios
- Philadelphia, PA36 estudios
- Seattle, WA34 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer (todos los tipos)90 estudios
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer del colon y del recto62 estudios
- Cáncer de ovario62 estudios
- Cáncer metastásico61 estudios
- Cáncer de próstata56 estudios
- Cáncer de endometrio51 estudios
- Depresión50 estudios
- Fallo cardíaco46 estudios
- Mieloma múltiple45 estudios
- Leucemia mielógena aguda44 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.